efavirenz (sustiva) Report issue

Small molecule Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.   NCATS

Chemistry

  • SMILES: FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC3CC3
  • InChIKey: XPOQHMRABVBWPR-ZDUSSCGKSA-N
  • Mol. Mass: 315.675
  • ALogP: 4.07
  • ChEMBL Molecule:
    efavirenz  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$1.9003 - $5.7008

United States

$2.0403 - $32.8517
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( efavirenz (sustiva), tenofovir (viread), emtricitabine (emtriva) - other name: emtricitabine; tenofovir    disoproxil fumarate; efavirenz )
|
( efavirenz (sustiva), lamivudine (epivir), zidovudine (retrovir) )
|
( efavirenz (sustiva), tenofovir (viread), lamivudine (epivir) - other names: efavirenz, lamivudine,and tenofovir disoproxil fumarate, symfi )

Alternative names

6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4s)-1,4-dihydro-2h-benzo[d][1,3]oxazin-2-one | (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2h-3,1-benzoxazin-2-one | bristol-myers squibb brand of efavirenz | dmp 266 | dmp-266 | du pont brand of efavirenz | efavirenz | (-)-efavirenz | éfavirenz | efavirenza | efavirenz / emtricitabine / tenofovir disoproxil fumarate | efavirenz / emtricitabine / tenofovir disoproxil maleate | efavirenz / emtricitabine / tenofovir disoproxil, phosphate | efavirenz / emtricitabine / tenofovir disoproxil succinate | efavirenz, (r)-isomer | efavirenz, (s)-isomer | efavirenzum | efavirenzy | l 743726 | l 743,726 | l-743726 | l-743,726 | merck sharp & dohme brand of efavirenz | mk0831 | nano-efavirenz | nano-lopinavir | (s)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one | (s)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2h-3,1-benzoxazin-2-one | (s)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one | stocrin | sustiva | sustiva 600 | united drug brand of efavirenz

Organizations (276)

Research & Development (263)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (50)

Approved Indications (1)


 

HIV Infections

Experimental Indications - Clinical Trial Phases 1-4 (50)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Alveolar Bone Loss (Phase 4)

Alzheimer Disease (Phase 1)

Antiretroviral Therapy, Highly Active (Phase 2)

Atrophy (Phase 4)

Breast Feeding (Phase 3)

Cardiovascular Diseases (Phase 4)

Central Nervous System (Phase 2)

Central Nervous System Diseases (Phase 4)

Contraception (Phase 2)

Cytochrome P-450 CYP2B6 (Phase 1)

Dementia (Phase 4)

Dentin Sensitivity (Phase 1/Phase 2)

Diabetes Mellitus, Type 2 (Phase 1)

Drug Interactions (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Drugs, Investigational (Phase 1)

Healthy Volunteers (Phase 4)

Hepacivirus (Phase 1)

Hepatitis B (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV-Associated Lipodystrophy Syndrome (Phase 4)

HIV Infections ()

HIV Seronegativity (Phase 1)

HIV Seropositivity (Phase 2)

Hyperlipidemias (Phase 1)

Infant, Premature (Phase 1)

Intestinal Neoplasms (Phase 1)

Lipodystrophy (Phase 4)

Liver Diseases (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Malaria (Phase 3)

Meningitis, Cryptococcal (Phase 4)

Metabolic Detoxication, Phase I (Phase 1)

Mitochondrial Diseases (Phase 4)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 2)

Parasitic Diseases (Phase 1/Phase 2)

Pharmacokinetics (Phase 1)

Pregnancy (Phase 3)

Pregnancy Complications (Phase 3)

Prostatic Neoplasms (Phase 2)

Protease Inhibitors (Phase 1)

Sarcoma, Kaposi (Phase 3)

Sexually Transmitted Diseases, Viral (Phase 1)

Substance-Related Disorders (Phase 1)

Tuberculosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 348
  • # of Trial Organizations: 263

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue